知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1390 条记录 (耗时 0.036 秒)

    Synthetic DNA vectors and methods of use
    2.
    发明授权
    Synthetic DNA vectors and methods of use 有权

    公开(公告)号：US11602569B2

    公开(公告)日：2023-03-14

    申请号：US17675899

    申请日：2022-02-18

    申请人： Intergalactic Therapeutics, Inc.

    发明人： Bruce C. Schnepp ,  Philip R. Johnson

    IPC分类号： A61K48/00 ,  C12N15/64 ,  C12N15/86

    摘要： Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.

    In-vivo Continuous Directed Evolution System and Application Thereof
    4.
    发明申请
    In-vivo Continuous Directed Evolution System and Application Thereof 有权

    公开(公告)号：US20230044600A1

    公开(公告)日：2023-02-09

    申请号：US17935605

    申请日：2022-09-27

    申请人： Jiangnan University

    发明人： Jing Wu ,  Zhanzhi Liu ,  Xinyu Zhang ,  Ying Xu

    IPC分类号： C12N15/10 ,  C12N15/64

    摘要： The disclosure discloses an in-vivo continuous directed evolution system and application thereof, and belongs to the fields of gene engineering and enzyme engineering. The system includes Escherichia coli host bacteria carrying a random mutation module mutagenesis plasmid, a programmed death module toxin-antitoxin system and a target gene expression module target plasmid. The modules are coupled with one another, and target genes are subjected to multiple rounds of continuous mutation by virtue of the random mutation module mutagenesis plasmid in the system, so that the mutation rate of the target genes is further increased, and ultimately, efficient evolution and screening of the target genes in the host bacteria are realized. According to the system, mutations are accurately positioned on the target genes, random mutations in non-target gene regions are reduced, and the system has good practical value and can be applied to directed evolution of various different functional proteins.

    LYSIN-ANTIMICROBIAL PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTS, LYSINS, ISOLATED POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF
    6.
    发明申请
    LYSIN-ANTIMICROBIAL PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTS, LYSINS, ISOLATED POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF 有权

    公开(公告)号：US20220402984A1

    公开(公告)日：2022-12-22

    申请号：US17816318

    申请日：2022-07-29

    申请人： CONTRAFECT CORPORATION

    发明人： Raymond SCHUCH

    IPC分类号： C07K14/47 ,  C12N15/64 ,  A61P31/04

    摘要： The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL). Exemplary lysin-AMP polypeptides, such as GN370 (SEQ ID NO: 44) as well as methods of treating bacterial infections using the present lysin-AMP polypeptide constructs are also disclosed.

    UNIVERSAL DNA ASSEMBLY
    8.
    发明申请
    UNIVERSAL DNA ASSEMBLY 有权

    公开(公告)号：US20220380784A1

    公开(公告)日：2022-12-01

    申请号：US17599616

    申请日：2020-04-02

    申请人： Oxford University Innovation Limited

    发明人： Da LIN ,  Katherine ROBINS ,  Chris O'CALLAGHAN

    IPC分类号： C12N15/64 ,  C12N15/11 ,  C12N9/22 ,  C12N9/10 ,  C12N15/66

    摘要： The invention relates to a nucleic acid comprising at least one methylation-protectable restriction element, the methylation-protectable restriction element comprising: (i) a type IIS restriction enzyme recognition sequence, or a partial type IIS restriction enzyme recognition sequence, that is recognised by a type IIS restriction enzyme that cleaves outside of the recognition sequence; (ii) a DNA methylase recognition sequence that is recognised and methylated by a DNA methylase, wherein the DNA methylase recognition sequence is identical to, or is encompassed within, the type IIS restriction recognition sequence, such that methylation of the nucleic acid by the DNA methylase methylates the type IIS restriction enzyme recognition sequence and protects the nucleic acid from cleavage by the type IIS restriction enzyme; and (iii) a recognition sequence for a sequence-specific DNA-binding protein, wherein the recognition sequence is positioned such that the binding of the sequence-specific DNA-binding protein overlaps with the DNA methylase recognition sequence such that binding of the sequence-specific DNA-binding protein is capable of preventing methylation of the type IIS restriction enzyme recognition sequence by the DNA methylase such that it is not protected from cleavage by the type IIS restriction enzyme. The invention further relates to associated methods of nucleic acid assembly.

    TGFbeta type II-type III receptor fusions
    10.
    再颁专利
    TGFbeta type II-type III receptor fusions 有权

    公开(公告)号：USRE49280E1

    公开(公告)日：2022-11-08

    申请号：US16375242

    申请日：2019-04-04

    申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

    发明人： Andrew Hinck ,  Luzhen Sun ,  Christian Zwieb

    IPC分类号： C07K14/00 ,  C12N15/85 ,  C07K14/495 ,  C07K14/71 ,  C12N15/64

    摘要： Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-β type II receptor (TβP?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-β type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-β type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-β type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-β isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-β isoforms, but not other ligands of the TGF-β superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).